Zymeworks to Present at Bloom Burton Healthcare Conference
April 13 2021 - 8:30AM
Business Wire
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced
that the Company will present at the upcoming 2021 Bloom Burton
Healthcare Investor Conference taking place April 20-21, 2021.
The Company’s presentation will be on Tuesday, April 20, 2021 at
11:30 a.m. ET.
Interested parties can access a live webcast of the presentation
via a link from Zymeworks’ website at
http://ir.zymeworks.com/events-and-presentations, which will also
host a recorded replay available afterwards.
About Zymeworks Inc. Zymeworks is a clinical-stage
biopharmaceutical company dedicated to the development of
next-generation multifunctional biotherapeutics. Zymeworks’ suite
of therapeutic platforms and its fully integrated drug development
engine enable precise engineering of highly differentiated product
candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25),
is a novel Azymetric™ bispecific antibody which has been granted
Breakthrough Therapy designation by the FDA and is currently
enrolling in a pivotal clinical trial for refractory HER2-amplified
biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2
clinical trials for HER2-expressing gastroesophageal and breast
cancers. Zymeworks’ second clinical candidate, ZW49, is a novel
bispecific HER2-targeting antibody-drug conjugate currently in
Phase 1 clinical development and combines the unique design and
antibody framework of zanidatamab with Zymeworks’ proprietary
ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep
preclinical pipeline in oncology (including immuno-oncology agents)
and other therapeutic areas. In addition, its therapeutic platforms
are being leveraged through strategic partnerships with nine
biopharmaceutical companies. For additional information about
Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210413005077/en/
Investor Inquiries: Ryan Dercho, Ph.D. (604) 678-1388
ir@zymeworks.com
Tiffany Tolmie (604) 678-1388 ir@zymeworks.com
Media Inquiries: Mary Klem (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Sep 2023 to Sep 2024